Table 2.
Characteristics of patients staying on DAPT during all follow-up
| Characteristic | Number (%) of patients remaining on DAPT at 12 months (n=6552) | p Value* | Number (%) of patients remaining on DAPT at the end of follow-up (n=4859) | p Value* |
|---|---|---|---|---|
| Age, years† | 0.55 | 0.018 | ||
| <50 | 1147/1517 (75.6) | 819/1517 (54.0) | ||
| 51–59 | 1949/2523 (77.2) | 1393/2523 (55.2) | ||
| 60–69 | 1848/2386 (77.5) | 1352/2386 (56.7) | ||
| 70–79 | 1230/1558 (78.9) | 916/1558 (58.8) | ||
| ≥80 | 464/608 (76.3) | 378/608 (62.2) | ||
| Sex | 0.59 | 0.91 | ||
| Male | 5072/6582 (77.1) | 3706/6582 (56.3) | ||
| Female | 1567/2011 (77.9) | 1153/2011 (57.3) | ||
| Region | <0.001 | <0.001 | ||
| Northern Europe | 2467/3008 (82.0) | 1825/3008 (60.7) | ||
| Southern Europe | 1495/1958 (76.4) | 1005/1958 (51.3) | ||
| Eastern Europe | 1372/1954 (70.2) | 1002/1954 (51.3) | ||
| Latin America | 1305/1673 (78.0) | 1027/1673 (61.4) | ||
| Centre type | <0.001 | <0.001 | ||
| University general | 2540/3370 (75.4) | 1913/3370 (56.8) | ||
| Non-university general | 1921/2487 (77.2) | 1335/2487 (53.7) | ||
| Regional/community/rural | 1471/1809 (81.3) | 1118/1809 (61.8) | ||
| Private | 707/927 (76.3) | 493/927 (53.2) | ||
| Type of ACS† | 0.16 | 0.68 | ||
| NSTE-ACS | 3262/4253 (76.7) | 2430/4253 (57.1) | ||
| STEMI | 3360/4314 (77.9) | 2415/4314 (56.0) | ||
| Diabetic status | 0.034 | 0.008 | ||
| Non-diabetic | 5142/6711 (76.6) | 3725/6711 (55.5) | ||
| Diabetic | 1497/1882 (79.5) | 1134/1882 (60.3) | ||
| Management strategy† | <0.001 | 0.25 | ||
| CABG (with/without PCI) | 40/50 (80.0) | 32/50 (64.0) | ||
| PCI only | 1679/2292 (73.3) | 3466/6205 (55.9) | ||
| Medication only | 1679/2292 (73.3) | 1339/2292 (58.4) | ||
| Unknown | 29/46 (63.0) | 22/46 (47.8) | ||
| Antiplatelet medication | 0.99 | <0.001 | ||
| Aspirin+clopidogrel | 5420/7829 (69.2) | 4495/7829 (57.4) | ||
| Aspirin+prasugrel | 500/705 (70.9) | 333/705 (47.2) | ||
| Aspirin+clopidogrel+prasugrel | 14/18 (77.8 | 10/18 (55.6) | ||
| Aspirin+ticlopidine | 30/41 (73.2) | 21/41 (51.2) | ||
| Glucose, mg/dL† | 0.19 | 0.061 | ||
| <160 | 4381/5709 (76.7) | 3194/5709 (55.9) | ||
| ≥160 | 1390/1763 (78.8) | 1056/1763 (59.9) | ||
| Creatine, mg/dL† | 0.17 | 0.88 | ||
| <1.2 | 5455/7041 (77.5) | 3959/7041 (56.2) | ||
| 1.2–1.6 | 549/713 (77.0) | 407/713 (57.1) | ||
| 1.6–2.0 | 154/200 (77.0) | 121/200 (60.5) | ||
| >2.0 | 129/167 (77.2) | 113/167 (67.7) | ||
| Haemoglobin, g/dL† | 0.68 | 0.055 | ||
| <13 | 1321/1683 (78.5) | 1020/1683 (60.6) | ||
| ≥13 | 4892/6357 (77.0) | 3512/6357 (55.2) |
*p Values calculated using Cox model with time to first switch from DAPT as the outcome.
†Data unavailable in 1 patient for age, 14 for type of ACS, 22 for management strategy, 1560 for glucose level, 259 for creatine level and 327 for haemoglobin level.
ACS, acute coronary syndrome; CABG, coronary artery bypass graft; DAPT, dual antiplatelet therapy; NSTE-ACS, non-ST elevation acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.